The impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients (pts) with transitional cell carcinoma (TCC) of the bladder.

被引：0
|
作者：
Dash, A [1 ]
Koppie, T [1 ]
Vora, K [1 ]
Bochner, B [1 ]
Galsky, MD [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：399S / 399S
页数：1
相关论文
共 50 条
  • [31] Phase I/II study of dose-dense sequential chemotherapy in renal impaired patients (Pts) with transitional cell carcinoma (TCC) of the urothelium.
    Galsky, MD
    Mironov, S
    Scattergood, J
    Dobrzynski, D
    Mitra, N
    Boyle, MG
    Bajorin, DF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 385S - 385S
  • [32] Differences in survival between patients with sarcomatoid carcinoma, carcinosarcoma and transitional cell carcinoma of the bladder.
    Black, Peter C.
    Wright, Jonathan L.
    Brown, Gordon A.
    Gomez, Jose A.
    Porter, Michael P.
    Kamat, Ashish M.
    Dinney, Colin P. N.
    Lin, Daniel W.
    [J]. JOURNAL OF UROLOGY, 2007, 177 (04): : 546 - 546
  • [33] TRANSITIONAL CELL-CARCINOMA OF THE OVARY - A MATCHED CONTROL STUDY OF ADVANCED-STAGE PATIENTS TREATED WITH CISPLATIN-BASED CHEMOTHERAPY
    GERSHENSON, DM
    SILVA, EG
    MITCHELL, MF
    ATKINSON, EN
    WHARTON, JT
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 168 (04) : 1178 - 1187
  • [34] Synchronous ipsilateral renal cell carcinoma and transitional cell carcinoma of the renal pelvic with complete remission of TCC after neoadjuvant chemotherapy
    Safadi, Ali
    Elias, Ibrahim
    Visoki, Alexander
    Zick, Anat
    Schwalb, Sergio
    Katz, Ran
    [J]. UROLOGY CASE REPORTS, 2018, 19 : 28 - 30
  • [35] 1260 formulas estimating creatinine clearance are inadequate for determining eligibility for cisplatin-based chemotherapy in bladder cancer
    Raj, GV
    Iasonos, A
    Galsky, MD
    Herr, HW
    Donat, SM
    [J]. JOURNAL OF UROLOGY, 2006, 175 (04): : 405 - 405
  • [36] Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy
    Keck, Bastian
    Wach, Sven
    Stoehr, Robert
    Kunath, Frank
    Bertz, Simone
    Lehmann, Jan
    Stoeckle, Michael
    Taubert, Helge
    Wullich, Bernd
    Hartmann, Arndt
    [J]. BMC CANCER, 2013, 13
  • [37] Phase II trial of adjuvant gemcitabine plus cisplatin-based chemotherapy in patients with locally advanced bladder cancer
    Jin, James O.
    Lehmann, Jan
    Taxy, Jerome
    Huo, Dezheng
    Stokle, Michael
    Vogelzang, Nicholas J.
    Steinberg, Gary
    Stadler, Walter M.
    [J]. CLINICAL GENITOURINARY CANCER, 2006, 5 (02) : 150 - 154
  • [38] Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer
    Muramaki, Mototsugu
    Miyake, Hideaki
    Kurahashi, Toshifumi
    Takenaka, Atsushi
    Inoue, Taka-Aki
    Fujisawa, Masato
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2008, 15 (04) : 314 - 318
  • [39] Expression of basic fibroblast growth factor (bFGF) mediates the tumorigenic phenotype in human transitional cell carcinoma (TCC) of the bladder.
    Wood, CG
    Perrotte, P
    Inoue, K
    Eve, B
    Dinney, CPN
    [J]. JOURNAL OF UROLOGY, 1998, 159 (05): : 283 - 283
  • [40] Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy
    Bastian Keck
    Sven Wach
    Robert Stoehr
    Frank Kunath
    Simone Bertz
    Jan Lehmann
    Michael Stöckle
    Helge Taubert
    Bernd Wullich
    Arndt Hartmann
    [J]. BMC Cancer, 13
12345